close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

99.85 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
News headline image
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
From BioNTech SE
Via GlobeNewswire
News headline image
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study ↗
 
Via Benzinga
News headline image
Why BioNTech Was a Sickly Stock This Week ↗
The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks. 
Via The Motley Fool
News headline image
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Starts Dosing In Herpes Vaccine Candidate Study ↗
 
Via Benzinga
Will Investors Notice Exciting Sign On BioNTech's Chart? ↗
 
Via Benzinga
News headline image
Three Pharma Stocks to Sell Before They Die ↗
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
News headline image
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech, Ryvu Therapeutics Join Forces For Immuno-Modulatory Candidates ↗
 
Via Benzinga
News headline image
Update on First BioNTainer for African-based mRNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
From BioNTech SE
Via GlobeNewswire
News headline image
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
News headline image
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review ↗
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
News headline image
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities ↗
 
Via Benzinga
News headline image
Why Is Novavax (NVAX) Stock Plunging Today? ↗
NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player. 
Via InvestorPlace
News headline image
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry ↗
At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗
 
Via Benzinga
News headline image
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off ↗
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
News headline image
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
From BioNTech SE
Via GlobeNewswire
News headline image
FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old ↗
 
Via Benzinga
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From BioNTech SE
Via GlobeNewswire
News headline image
US Supports Delay On COVID Patent Waiver Extension Decision ↗
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health... 
Via Benzinga
News headline image
UK's Regulatory Agency Backs Pfizer/BioNTech's COVID-19 Vaccine For Youngest Kids ↗
 
Via Benzinga
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
News headline image
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
From BioNTech SE
Via GlobeNewswire
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These two companies are facing short-term issues that are likely to give way to long-term success. 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today